DXCM DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.…
Industry Peers
Medical DevicesKey Statistics
About DexCom (NASDAQ: DXCM)
›
DexCom (NASDAQ: DXCM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 11,000 employees.
The shares were at 80.19 USD on 19 November 2026, up 38.2% over 52 weeks. Its 52-week range is 54.11 USD to 92.59 USD: the price is 13.4% below the high and 48.2% above the low.
At a market capitalisation of 29.91B USD, it trades at 31.6 times trailing earnings and 25.6 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.4, a premium of 24% for DXCM.
DexCom reports return on equity of 30.5%, an operating margin of 24.0% and revenue up 11.2% year over year.
It holds more cash than debt, a net cash position of 425.00M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 26 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 98.58 USD is 22.9% above the current price. The next earnings report is expected on 11 February 2027.